CClinicalTrials.gg
Status unknownNCT03391817Updated Aug 15, 2019

FAECAL MICROBIOTA TRANSPLANTATION IN OBESITY

An interventional study of Fecal microbiota transplantation in Obesity, Morbid, sponsored by Joint Authority for Päijät-Häme Social and Health Care. Status unknown at 2 sites in Finland. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-08-15.

Sponsored by Joint Authority for Päijät-Häme Social and Health Care · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

40 patients meeting the criteria for obesity surgery are enrolled. Fecal microbiota transplantation (FMT) will be administered in gastroscopy 6 months before obesity surgery. 20 of the patients will receive a fecal transplant of a thin donor and 20 will receive placebo - a transplant made of their on feces. Changes in weight, laboratory values, general well being and stool microbiota will be measured up to one year after the surgery; one and a half years after FMT. The hypothesis is that FMT and the change in gut microbiota will help to reduce and maintain lower weight.

02

Conditions studied

  • Obesity, Morbid
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Candidates for the bariatric surgery

BMI ≥ 40 or BMI ≥35 and at least two obesity-related co-morbidities such as type II diabetes (T2DM), hypertension, sleep apnea and other respiratory disorders, non-alcoholic fatty liver disease, osteoarthritis, lipid abnormalities, gastrointestinal disorders, or heart disease.

  • Availability of consecutive fecal samples during one year
  • Compliance to attend gastroscopy and FMT
  • 18-65 years

Exclusion criteria

Exclusion Criteria:

  • Unable to provide informed consent
  • Pregnancy
  • Type I Diabetes Mellitus
  • Severe renal insufficiency, GFR\<30%
  • Chronic or recurrent bacterial infection needing antimicrobial treatment
  • Large hiatal hernia
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Intervention arm

    Fecal transplant from a thin donor

    Other: Fecal microbiota transplantation

  • Placebo comparator
    Placebo arm

    Fecal transplant made from patients own feces

    Other: Fecal microbiota transplantation

Interventions

  • OtherFecal microbiota transplantation

    Fecal microbiota transplantation administered in gastroscopy

05

What researchers measure

Primary outcomes

  1. Reduction of weight

    Time frame: 1,5 years

06

Study locations

2 of 2 sites recruiting
  • Helsinki University Hospital
    Helsinki, Finland
    Recruiting
  • Päijät-Häme Central Hospital
    Lahti, Finland
    Recruiting
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03391817
Lead sponsor
Joint Authority for Päijät-Häme Social and Health Care
Collaborators
University of Helsinki, Helsinki University Central Hospital
Responsible party
Sponsor
First posted
Jan 5, 2018
Start date
Jan 19, 2018
Primary completion
Feb 28, 2021 (estimated)
Completion
Feb 28, 2021 (estimated)
Last update
Aug 15, 2019

Study contacts

Perttu Lahtinen, MD
Contact
perttu.lahtinen@phhyky.fi
+358447195256
Perttu Arkkila, PhD MD
study director · Helsinki University Central Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion